(4-Phenylalanine)oxytocin, an inhibitor of the antidiuretic effect of 8-arginine-vasopressin.
[4-Phenylalanine]oxytocin was prepared from Z-Cys(Bzl)-Tyr(Bzl)-Ile-Phe-Asn-Cys(Bzl)-Pro-Leu-Gly-NG2 (4) by deprotection with Na in NH3 followed by cyclization of the resulting disulfhydryl compound with ICH2CH2I. The protected peptide 4 was prepared from Boc-Asn-Cys(Bzl)-Pro-Leu-Gly-NH2 by the stepwise solution method. Coupling was effected by a modification of the dicyclohexylcarbodiimide-1-hydroxybenzotriazole preactivation method wherein the precipitate of dicyclohexylurea is removed by filtration prior to mixing of the amino and carboxyl components. The analog was found to be an effective inhibitor of the antidiuretic (ADH) response to exogenous arginine-vasopressin. It produced marked diuresis in the anti-ADH assay at approximately the same dose level as does [Leu4]oxytocin but, in contrast to [Leu4]oxytocin, showed natriuretic activity only at relatively high dose levels. In addition, [Phe4]oxytocin exhibited 0.15% of the oxytocic potency of oxytocin, weak antiavian vasodepressor activity (pA2 = 6.93), and no measurable rat pressor activity.
D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives; D001794:Blood Pressure / Q000187:drug effects; D002645:Chickens; D003864:Depression, Chemical; D004231:Diuresis / Q000187:drug effects; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D010121:Oxytocin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D010649:Phenylalanine / Q000138:chemical synthesis / Q000494:pharmacology; D051381:Rats; D014590:Uterine Contraction / Q000187:drug effects; D014667:Vasopressins / Q000031:analogs & derivatives*
D014667:Vasopressins; D001127:Arginine Vasopressin; D010649:Phenylalanine; D010121:Oxytocin